Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...
Doctors say although screenings typically begin at the age of 45, they are seeing an increase in younger patients developing colon cancer.
The chronic autoimmune conditions — both considered types of inflammatory bowel disease — cause a myriad of symptoms ...
Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to ...
Gene therapies have the potential to cure some diseases, but they are extraordinarily expensive. Location can also be a big ...
The U.S. Food and Drug Administration (FDA) has granted traditional approval to Braftovi (encorafenib) for adult patients ...
USA News Group News Commentary, The global oncology market is on track to nearly triple in value over the next decade, growing from $279.98 billion in 2026 to an estimated $748.17 billion by 2035[1].
A Miami-based doctor points out the high incidence of colorectal cancer in the Black community and lauds new blood tests that may help patients who lack access to other health care options.
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, Baystreet.ca News Commentary, The global oncology and cancer drugs market, valued at $167 billion in 2023, is projected to reach $335.2 billion ...
Cartography Biosciences, Inc., a clinical-stage biotechnology company advancing a differentiated pipeline of antibody-based cancer therapies, today announced that the first patient has been dosed in a ...
Data presented at 16th World ADC London Summit with lead programme in colorectal cancer highlight the promise of Promatix’s proteomics-based ...
The SCREESCO trial reveals that colorectal cancer screening at 60 enhances early diagnosis without affecting overall mortality or increasing long-term risks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results